Sichuan Goldstone Asia Pharmaceutical Inc. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 711.44 million compared to CNY 731.93 million a year ago. Revenue was CNY 711.44 million compared to CNY 731.93 million a year ago.

Net income was CNY 107.01 million compared to CNY 80.94 million a year ago. Basic earnings per share from continuing operations was CNY 0.27 compared to CNY 0.2 a year ago. Diluted earnings per share from continuing operations was CNY 0.27 compared to CNY 0.2 a year ago.